Latvia - Latvia - Zāļu valsts aģentūra

sandoz d.d., slovenia - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg

Latvia - Latvia - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Latvia - Latvia - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - sitagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg

Kesatuan Eropah - Latvia - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - prostatas audzēji - endokrīnā terapija - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Kesatuan Eropah - Latvia - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - cukura diabēts, 2. tips - cukura diabēts - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 un 5. 1 pieejamo datu par dažādām kombinācijām).

Latvia - Latvia - Zāļu valsts aģentūra

elvim, sia, latvia - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Latvia - Latvia - Zāļu valsts aģentūra

elvim, sia, latvia - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg

Kesatuan Eropah - Latvia - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Latvia - Latvia - Zāļu valsts aģentūra

sanoswiss uab, lithuania - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/850 mg

Latvia - Latvia - Zāļu valsts aģentūra

sanoswiss uab, lithuania - vildagliptinum, metformini hydrochloridum - apvalkotā tablete - 50 mg/1000 mg